stockrowOpus Genetics, Inc.
Opus Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.2 million, up 29.1% from fiscal 2024.
- Revenue
- −73.8%
- EPS
- +33.3%
- Free cash flow
- −16.4%
Quarter to June 2026, against a year earlier
Follow IRD
Alert me
Opus Genetics, Inc. (IRD) EV/Sales
As of 6 November 2026, Opus Genetics, Inc. (IRD) trades at a EV/Sales of 35.0×. Over the past ten years it has ranged from −1.8× (December 2024) to 53.4× (September 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.7× | 3,578.66% |
| FY2024 | 0.2× | (81.48%) |
| FY2023 | 0.8× | 23.50% |
| FY2022 | 0.7× | (96.21%) |
| FY2021 | 17.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 34.4× | 22.34% |
| Mar 2026 | 28.1× | 390.85% |
| Dec 2025 | 5.7× | (3.75%) |
| Sep 2025 | 5.9× | 223.37% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AGMB AgomAb Therapeutics NV compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. compare | 0.4× |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 1.8× |
| FENC Adherex Technologies Inc. compare | 5.4× |
| OBIO Orchestra BioMed Holdings, Inc. compare | 9.0× |
| SRZN Surrozen, Inc. compare | 22.7× |
| IRD Opus Genetics, Inc. | 35.0× |
| PROK ProKidney Corp. compare | 40.7× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)